Stay updated with breaking news from Evogene. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Evogene (TSE:EVGN – Free Report) had its price objective reduced by Pi Financial from C$5.00 to C$4.00 in a research note released on Wednesday, BayStreet.CA reports. Evogene Price Performance Evogene Company Profile (Get Free Report) Evogene is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including […] ....
StockNews.com began coverage on shares of Evogene (NASDAQ:EVGN – Free Report) in a report released on Wednesday. The firm issued a sell rating on the biotechnology company’s stock. Evogene Trading Down 5.0 % NASDAQ EVGN opened at $0.63 on Wednesday. The business’s fifty day moving average is $0.79 and its 200 day moving average is […] ....
Silverarc Capital Management LLC raised its holdings in Evogene Ltd. (NASDAQ:EVGN – Free Report) by 3,000.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,100,000 shares of the biotechnology company’s stock after purchasing an additional 3,000,000 shares during the quarter. Silverarc Capital […] ....
Evogene Ltd. (NASDAQ:EVGN – Get Free Report) saw a significant decrease in short interest in December. As of December 15th, there was short interest totalling 187,200 shares, a decrease of 35.0% from the November 30th total of 287,800 shares. Based on an average daily volume of 144,100 shares, the days-to-cover ratio is presently 1.3 days. […] ....
Evogene (TSE:EVGN – Free Report) had its price objective cut by Echelon Wealth Partners from C$6.25 to C$6.00 in a report released on Friday morning, BayStreet.CA reports. They currently have a buy rating on the stock. Separately, Desjardins cut their target price on shares of Evogene from C$4.50 to C$4.25 and set a buy rating […] ....